Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know

In the latest close session, Medpace (MEDP) was up +1.38% at $319.16. The stock's performance was ahead of the S&P 500's daily gain of 0.54%. Elsewhere, the Dow gained 0.52%, while the tech-heavy Nasdaq added 0.74%. The provider of outsourced clinical development services's shares have seen an increase of 4.01% over the last month, surpassing the Medical sector's loss of 2.12% and falling behind the S&P 500's gain of 4.2%.Investors will be eagerly watching for the performance of Medpace in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 21, 2025. The company is forecasted to report an EPS of $3, showcasing a 9.09% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $541.19 million, showing a 2.48% escalation compared to the year-ago quarter. For the full year, the Zacks Consensus Estimates project earnings of $12.68 per share and a revenue of $2.18 billion, demonstrating changes of +0.4% and +3.58%, respectively, from the preceding year. It is also important to note the recent changes to analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.24% fall in the Zacks Consensus EPS estimate. Medpace is currently a Zacks Rank #3 (Hold). Digging into valuation, Medpace currently has a Forward P/E ratio of 24.83. This indicates a premium in contrast to its industry's Forward P/E of 15.37. We can additionally observe that MEDP currently boasts a PEG ratio of 5.69. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical Services was holding an average PEG ratio of 1.43 at yesterday's closing price. The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 91, this industry ranks in the top 37% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medpace Holdings, Inc. (MEDP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks